[(2-Oxoethyl)imino]diacetic acid | 204838-96-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2-Oxoethyl)imino]diacetic acid
• 英文别名: 2-[carboxymethyl(2-oxoethyl)amino]acetic acid
• CAS: 204838-96-0
• 化学式: C₆H₉NO₅
• 分子量: 175.14
• InChiKey: YDAYNDSXGSPJJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  94.9
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS
  申请人：LIFE TECHNOLOGIES CORPORATION

  公开号：US20160025713A1

  公开（公告）日：2016-01-28

  The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula A(B)n, wherein A is a fluorophore, B is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody. The present invention provides specific fluorescent compounds and methods used to detect and label fusion proteins that contain a poly-histidine affinity tag. These compounds have the general formula A(L)m(B)n wherein A is a fluorophore, L is a linker, B is an acetic acid binding domain, m is an integer from 1 to 4 and n is an integer from 1 to 6. The acetic acid groups interact directly with the positively charged histidine residues of the affinity tag to effectively label and detect a fusion protein containing such an affinity tag when present in an acidic or neutral environment.

  本发明提供了一种方法和荧光化合物，通过选择性地与亲和标签结合，从而促进融合蛋白的检测和标记。所述荧光化合物具有通式A(B)n，其中A是荧光团，B是带电化学基团、蛋白质或其片段的绑定域，n是1-6的整数，但该蛋白质或其片段不是抗体或由抗体产生的。本发明还提供了特定的荧光化合物和方法，用于检测和标记含有聚组氨酸亲和标签的融合蛋白。这些化合物具有通式A(L)m(B)n，其中A是荧光团，L是连接器，B是醋酸绑定域，m是1到4的整数，n是1到6的整数。醋酸基团直接与亲和标签中的正电荷组氨酸残基相互作用，有效地标记和检测含有此类亲和标签的融合蛋白，当其存在于酸性或中性环境中时。
• CHELATING MONOMERS AND POLYMERS
  申请人：Zhang Hongmin

  公开号：US20070254378A1

  公开（公告）日：2007-11-01

  This invention provides chelating moieties that comprise an aryl group. Monomers that include the chelating moieties can be polymerized into chelating polymers. Chelating polymers are useful to chelate metals. Chelating polymers in the form of metal chelates are useful for binding analytes, such as polypeptides that comprise histidine residues. Chelating polymers can be includes in articles such as chips and chromatographic materials.

  本发明提供了包含芳基的螯合基团。包括螯合基团的单体可以聚合成螯合聚合物。螯合聚合物可用于螯合金属。以金属螯合物形式的螯合聚合物可用于结合分析物，例如包含组氨酸残基的多肽。螯合聚合物可以包含在芯片和色谱材料等物品中。
• Novel quaternary ammonium compounds
  申请人：Sasahara Takehiko

  公开号：US20070203115A1

  公开（公告）日：2007-08-30

  A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):

  一种抑制回肠胆汁酸转运蛋白活性的方法，包括向该受试者施用一种由式（1）所代表的化合物的有效量：
• PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS
  申请人：Satyam Apparao

  公开号：US20110269722A1

  公开（公告）日：2011-11-03

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了式(I)化合物或其药学上可接受的盐。本发明还提供了包含一个或多个式(I)化合物或其中间体以及一个或多个药学上可接受的载体、车载物或稀释剂的制药组合物。本发明还提供了制备方法和使用方法，其中包括NO释放前药、双前药和相互前药的前药，其中包括式(I)化合物。
• Prodrugs Containing Bio-Cleavable Linkers
  申请人：Piramal Life Sciences Limited

  公开号：EP2075011A2

  公开（公告）日：2009-07-01

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了式 (I) 化合物或其药学上可接受的盐。本发明还提供了包含一种或多种式 I 化合物或其中间体以及一种或多种药学上可接受的载体、载体或稀释剂的药物组合物。本发明进一步提供了包括NO释放原药、双原药和包含式I化合物的互作原药在内的原药的制备方法和使用方法。